| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Zura Bio Limited | Crebankitug (ZB-168) | Sjögren-Larssons Syndrome (SLS) | Phase 2 | Trial Planned | Intravenous | Genetic Disorder |
| Zura Bio Limited | ZB -168 | Ulcerative Colitis | Phase 2 | Trial Planned | Oral | Gastroenterology |
| Zura Bio Limited | Crebankitug (ZB-168) | Atopic dermatitis | Phase 2 | Trial Planned | Intravenous | Immunology |
| Zymeworks Inc. | Ziihera (zanidatamab-hrii) - (HERIZON-GEA-01) | First-line HER2-positive gastroesophageal adenocarcinoma (GEA) | Phase 3 | Data Released | Intravenous infusion | Oncology |
| Zymeworks Inc. | Ziihera (zanidatamab-hrii) - (HERIZON-GEA-01) | First-line HER2-positive gastroesophageal adenocarcinoma (GEA) | Phase 3 | Data Released | Intravenous infusion | Oncology |
| Zymeworks Inc. | Zanidatamab (ZW25) - (HERIZON‚ÄëGEA‚Äë01) | HER2-positive Gastroesophageal Adenocarcinoma (GEA) | Phase 3 | Ongoing | Intravenous | Oncology |
| Zymeworks Inc. | Zanidatamab (ZW25) - (mGEA) | HER2-expressing Gastrointestinal Cancers (Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer) | Phase 2 | Data Released | Intravenous | Oncology |
| Zymeworks Inc. | Zanidatamab (ZW25) with IBRANCE (palbociclib) and Fulvestrant | 3L+ HER2-positive, HR-positive breast cancer | Phase 2 | Data Released | Intravenous Oral Intramuscular | Oncology |